aXichem AB (publ), a developer of natural analogue industrial compounds, announces that results from a new clinical study proves that a low dose of aXichem’s phenylcapsaicin product, aXivite, has a significant effect in a decrease in % of body fat. The study also shows significant results in important blood bio-markers related to general gut health.
The clinical trial was conducted as a randomized, double-blind, clinical trial of male and female subjects at an investigational center in Northeast Ohio, US. The study was conducted to outline efficacy on the effects of phenylcapsaicin on weight loss and body composition.
“We are very pleased and excited over the significance in the results and the outcome of this clinical trial. During the eight week clinical trial 39 participants concluded a program including exercise and controlled calorie intake. These results are the proof of concept that aXichem has been waiting for and it looks promising for aXivite’s future investigations and market success.”, says Torsten Helsing, CEO of aXichem.
“I’m looking forward to present these convincing results to our partners and distributors, active in the field of nutrition products for weight control. It is a growing market and aXivite has all the characteristics to become a competitive ingredient in future weight control and gut health products.”, says Lucas Altepost, vice President and VP Sales and Marketing at aXichem.
The U.S. market for weight management products amounted to about 66 billion USD in 2017 according ResearchAndMarkets.com. The global market for weight management and weight control products is expected to reach over 442 billion USD year 2025, with a calculated average growth rate of about 8.2% for the period according to marketwatch.com.
This press release was submitted by the contact person below on 2 June 2021, at 13:00 CET.